Vaccination differences among U.S. adults by their self-identified sexual orientation, National Health Interview Survey, 2013–2015

Anup Srivastav, Alissa O’Halloran, Peng-Jun Lu, Walter W. Williams, Sonja S. Hutchins

1 Leidos Inc., Atlanta, Georgia, United States of America, 2 Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 3 Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 4 Morehouse School of Medicine, Atlanta, Georgia, United States of America

These authors contributed equally to this work.

* xbs2@cdc.gov

Abstract

Introduction

Very few studies have explored the associations between self-identified sexual orientation and comprehensive vaccination coverage. Most of the previous studies that reported health disparities among lesbian, gay and bisexual populations were not based on a nationally representative sample of U.S. adults, limiting the generalizability of the findings. Starting in 2013, the National Health Interview Survey (NHIS) included questions to ascertain the adult’s self-identified sexual orientation that allowed national level vaccination estimation by sexual orientation. This study examined associations of self-reported vaccination coverage for selected vaccines among U.S. adults by their sexual orientation.

Methods

We analyzed combined data from 2013–2015 NHIS, a nationally representative probability-based health survey of the noninstitutionalized U.S. population ≥ 18 years. For vaccines other than influenza, weighted proportions were calculated. Influenza coverage was calculated using the Kaplan-Meier procedure. Multivariable logistic regression models were used to calculate adjusted prevalence differences for each vaccine overall and stratified by sexual orientation and to identify factors independently associated with vaccination.

Results

Significant differences were observed by sexual orientation for self-reported receipt of human papillomavirus (HPV), hepatitis A (HepA), hepatitis B (HepB), and influenza vaccination. Bisexual females (51.6%) had higher HPV coverage than heterosexual females (40.2%). Gay males (40.3%) and 53.6%, respectively) had higher HepA and HepB coverage than heterosexual males (25.4% and 32.6%, respectively). Bisexual females (33.9% and 58.5%, respectively) had higher HepA and HepB coverage than heterosexual females.
(23.5% and 38.4%, respectively) and higher HepB coverage than lesbian females (45.4%). Bisexual adults (34.1%) had lower influenza coverage than gay/lesbian (48.5%) and heterosexual adults (43.8%). Except for the association of having self-identified as gay/lesbian orientation with greater likelihood of HepA, HepB, and influenza vaccination, sexual orientation was not associated with higher or lower likelihood of vaccination. Health status or other behavioral characteristics studied had no consistent relationship with vaccination among all populations.

**Conclusion**

Differences were identified in vaccination coverage among the U.S. adult population by self-reported sexual orientation. This study is the first to assess associations of sexual orientation with a comprehensive list of vaccinations. Findings from this study can serve as a baseline for monitoring changes over time. All populations could benefit from improved vaccination.

**Introduction**

Comprehensive vaccination is critical in preventing the acquisition and transmission of many serious communicable infections [1–10]. Influenza vaccination is recommended for all adults each year. Other adult vaccinations are recommended for specific populations based on a person’s age, health conditions, behavioral risks, occupation, travel, and other indications (https://www.cdc.gov/vaccines/schedules/hcp/adult.html).

Differences in the receipt of select vaccines have been reported between persons who self-identify as lesbian, gay, or bisexual versus heterosexual populations [11–29]. Higher behavioral risks and lower rates of preventive care have been reported in lesbian and bisexual women compared with heterosexual women [30,31]. For example, prior surveillance has indicated that human papillomavirus (HPV) vaccination among sexual minority women (including lesbians, bisexual, and other women who have sex with women) remains low [23–25]. Sexual minority men, specifically men who identify as gay, bisexual, or as an MSM (men who have sex with men), have been reported to have an elevated risk for certain vaccine preventable infections, including infections due to HPV, hepatitis A virus (HAV), and hepatitis B virus (HBV), attributed to transmission through anal intercourse [1,2,32]. Disparities in HPV, hepatitis A (HepA), and hepatitis B (HepB) infections that burden sexual minority populations may be related to differential vaccination uptake compared with heterosexual adults [23–29]. With implementation of the Affordable Care Act, sexual minority adults experienced reduced barriers to accessing primary health care and health care affordability [30,33–37]. The extent to which health care providers can capitalize on the health care visits of sexual minority adults to increase comprehensive vaccination warrants exploration.

Limited research has evaluated the associations of sexual orientation with vaccination uptake [11–29]. Starting in 2013, the National Health Interview Survey (NHIS), which routinely conducts surveillance of vaccination histories, included questions to ascertain adult sexual orientation. Using data from the 2013, 2014, and 2015 NHIS cycles, this study examines vaccination differences among U.S. adults by their self-identified sexual orientation and explores factors associated with vaccination for selected vaccines. We hypothesized that self-identified gay/lesbian or bisexual populations will have higher coverage for select vaccines compared with heterosexual adults and there will be differences in coverage for select vaccines.
among sexual minorities. Because of greater use of health services among gay/lesbian adults and the generally higher acceptability of vaccines in these groups [29] and because HPV, hepatitis A (HepA), and hepatitis B (HepB) vaccinations protect against sexually transmitted infections, persons at higher risk of acquiring these infections because of risky sexual behaviors might be expected to have higher coverage for those vaccines.

**Material and methods**

The NHIS was approved by the Research Ethics Review Board (ERB number, 2009–16) of the National Center for Health Statistics, CDC and designated as “Public Health Non-Research” during the determination for applicability of human subjects’ regulations, because the activity is not intended to include applicable research, but to access the implementation, coverage, performance, and/or satisfaction with an existing public health program, service, function, intervention or recommendation. Data security was addressed and written informed consent was sought.

**Survey description**

The NHIS is a nationally representative probability-based health survey of the civilian noninstitutionalized U.S. population conducted continuously throughout the year by the National Center for Health Statistics of the Centers for Disease Control and Prevention [38]. The NHIS uses a complex sampling design involving stratification, clustering, and multistage sampling. Results obtained from samples are weighted to the adult civilian noninstitutionalized U.S. population to minimize non-response bias. Starting in 2013, questions allowing self-identification of sexual orientation were added to the survey. The adult questionnaire is completed by one randomly selected adult aged ≥18 years within each family in the household. This questionnaire included questions on receipt of recommended vaccines. Three years of data from 2013, 2014, and 2015 NHIS were combined to get an adequate sample size of lesbian, gay, and bisexual adults. The combined sample for this analysis was 101,091 adults aged ≥18 years. There are no unique personal identifiers in the NHIS that would allow determination of repeat respondents in this study across data recruitment waves. In 2013, 2014, and 2015, the final response rates among adults were 61.2%, 58.9%, and 55.2%, respectively [39–41].

**Sexual orientation assessment**

To ascertain the adult’s self-identification of sexual orientation, four cascading questions were asked of all sample adults aged ≥18 years. The first question asked, “Which of the following best represents how you think of yourself?” The response options for males were: gay; straight, that is, not gay; bisexual; something else; and I don’t know the answer. The response options for females were: lesbian or gay; straight, that is, not lesbian or gay; bisexual; something else; and I don’t know the answer. In the 2013 and 2014 NHIS, respondents who answered “something else” or “I don’t know the answer” were asked one or more follow-up question(s) to gather additional information on their sexual orientation, while no follow-up question(s) were asked of respondents in the 2015 NHIS. Data from the 2013 and 2014 NHIS follow-up questions were not used in this study. Respondents answering “something else” (0.2%), “I don’t know the answer” (0.5%), and refused (0.5%) were classified as missing and excluded from the analysis.

**Vaccination variables**

Responses to selected survey questions were used to measure associations between self-identified sexual orientation and self-reported receipt of selected vaccines (HPV) [females and males
Aged 18–26 years, HepA [ever received; adult aged ≥18 years with high risk for HAV infection], HepB [ever received; adults aged ≥18 years with high risk for HBV infection], influenza [shot or spray], pneumococcal [adults aged 18–64 years at increased risk for pneumococcal disease and aged ≥65 years], tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine [Tdap; analysis was limited to individuals who were able to say they received Td or Tdap during 2005 or later], and shingles vaccine [herpes zoster, adults aged ≥60 years]).

**Sociodemographic and health behavior variables**

Sociodemographic and health behavior variables included: demographic characteristics (age, sex, race/ethnicity, education, employment, poverty status); access to healthcare (having health insurance, having a usual place for healthcare, physician contact within the past year); health behaviors (smoking status, consuming five or more alcoholic drinks in one day at least once in the past year, ever being tested for HIV, meeting federal guidelines for aerobic physical activity, self-selected health status); selected health conditions (asthma, diabetes, obesity, cardiovascular disease, chronic liver disease, disability); and travel status (ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 where HAV and/or HBV infections are endemic). Poverty status was defined according to the ratio of a family’s total income to the federal poverty threshold. Federal poverty thresholds are updated annually by the U.S. Census Bureau (https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html).

**Increased risk for pneumococcal, hepatitis A, and hepatitis B infections**

**Pneumococcal disease.** The presence of selected conditions that increase risk for pneumococcal disease was determined by responses to questions in the NHIS. Adults were considered at increased risk for pneumococcal disease if they had ever been told by a doctor or other health professional that they had diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other heart condition; had a diagnosis of cancer during the previous 12 months (excluding nonmelanoma skin cancer); had ever been told by a doctor or other health professional that they had lymphoma, leukemia, or blood cancer; or they had been told by a doctor or other health professional that they had chronic bronchitis or weak or failing kidneys during the preceding 12 months or had an asthma episode or attack during the preceding 12 months; or they were current smokers.

For HepA and HepB vaccination, data were collected on selected respondent characteristics that increase the risk for infection (travel to countries in which HAV infections are endemic and having chronic liver disease; travel to countries in which HBV infections are endemic, and having diabetes or chronic liver disease, respectively) [3,5].

**Hepatitis A.** All adults were considered at high-risk behavior for HAV infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor; or other health professional that they had any kind of chronic, or long-term liver condition.

**Hepatitis B.** All adults were considered at high-risk behavior for HBV infection if they reported any one of the following risk factors: if they had ever been told by a doctor or other health professional that they had diabetes; ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995; or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.
Data analysis

SUDAAN statistical software (Software for the statistical analysis of correlated data, Research Triangle Institute, Research Triangle Park, NC, version 11.0.1) was used to calculate point estimates and 95% confidence intervals for specified outcome variables. T-tests were used to determine differences between demographic and other characteristics stratified by sexual orientation. Statistical significance was defined as $p < 0.05$. For vaccines other than influenza, the weighted proportion of respondents who reported vaccination was calculated. To better assess seasonal influenza vaccination coverage combined for the 2013–14 and 2014–15 influenza seasons, we reported coverage restricted to individuals interviewed during August 2013 through June 2014, and vaccinated during July 2013 through May 2014 for the 2013–14 influenza season, and individuals interviewed during August 2014 through June 2015, and vaccinated during July 2014 through May 2015 for the 2014–15 influenza season using the Kaplan-Meier survival analysis procedure [42–44].

Adjusted prevalence differences were estimated for each vaccine overall and stratified by sexual orientation using predictive marginals under multivariable logistic regression models. Adjusted estimates for the ‘overall’ model were produced by adjusting for age, sex, race/ethnicity, education, employment status, poverty status, physician contact within the past year, usual place of healthcare, health insurance status, self-reported smoking status, five or more alcoholic drinks in one day at least once in past year for men/four or more alcoholic drinks in one day at least once in the past year for women, HIV test status, self-reported health status, obesity status (defined as having body mass index $\geq 30$), history of asthma, diabetes status, cardiovascular disease status, chronic liver disease status, disability status, met Federal guidelines for aerobic physical activity (using 2008 Guidelines criteria [45], respondents were classified as aerobically active if they reported $\geq 150$ minutes/week of light- to moderate-intensity activity, 75 minutes/week of vigorous-intensity activity, or an equivalent combination of the two), and sexual orientation, and in addition, travel status for HAV and HBV vaccination coverage estimates. These variables were adjusted for in the multivariable logistic regression models, because these variables have been shown to be associated with vaccination.

Being the primary exposure of interest, sexual orientation was not controlled for except in the “overall” multivariable regression model(s). Adjusted estimates for the ‘stratified by sexual orientation’ model were produced by controlling for all variables adjusted for in the ‘overall’ model except the sexual orientation variable, which allowed reporting of adjusted vaccination coverage levels among the study population stratified on their sexual orientation. The adjusted prevalence differences (controlling for all variables included in the ‘overall’ model) were used to identify factors independently associated with vaccination, which allowed assessment of sexual orientation as an independent factor of vaccination.

Results

Table 1 presents the percent distribution of sexual orientation by selected demographic, access to healthcare, health behavior, and health condition characteristics. Among adults aged $\geq 18$ years, 97.6% self-identified as heterosexual, 1.6% as gay/lesbian, and 0.7% as bisexual. Respondents identifying as gay/lesbian and bisexual were more likely to report current smoking, consuming five or more alcoholic drinks in one day at least once in the past year, testing for HIV, and to have asthma compared with respondents identifying as heterosexual. Respondents identifying as gay/lesbian and bisexual differed from respondents identifying as heterosexual on a number of other demographic and access characteristics (Table 1).

Table 2 presents the unadjusted self-reported vaccination coverage of selected vaccines among adults aged $\geq 18$ years, overall and by sexual orientation. Overall HPV vaccination
Table 1. Characteristics of participants aged ≥18 years in the United States by demographic characteristics, health conditions, health behaviors, healthcare access, vaccination status, and self-identified sexual orientation–National Health Interview Survey, 2013–2015.

|                                | Heterosexual | Gay/Lesbian | Bisexual |
|--------------------------------|--------------|-------------|----------|
|                                | Sample (n)   | Weighted %  | Sample (n) | Weighted %  | Sample (n) | Weighted %  |
| **Overall**                    | 98,582       | 97.6        | 1,718     | 1.6         | 791        | 0.7         |
| **Age group (years)**          |              |             |           |             |           |             |
| 18–49                          | 49,707       | 55.1        | 1,063     | 64.5\(^a\)  | 626        | 81.6\(^b,c\) |
| 50–64                          | 25,231       | 25.9        | 468       | 26.4        | 113        | 12.9\(^b,c\) |
| 65 and over                    | 23,644       | 19.0        | 187       | 9.1\(^a\)   | 52         | 5.5\(^b,c\)  |
| **Sex**                        |              |             |           |             |           |             |
| Male                           | 44,057       | 48.3        | 930       | 54.6\(^a\)  | 237        | 29.0\(^b,c\) |
| Female                         | 54,525       | 51.7        | 788       | 45.4        | 554        | 71.0        |
| **Race/ethnicity**             |              |             |           |             |           |             |
| Non-Hispanic white             | 60,449       | 65.6        | 1,085     | 66.4        | 513        | 69.7        |
| Non-Hispanic black             | 13,504       | 11.5        | 242       | 12.7        | 104        | 10.5        |
| Hispanic                       | 16,565       | 15.3        | 266       | 14.2        | 111        | 11.9\(^b\)  |
| Non-Hispanic other, multiple races | 8,064     | 7.5         | 125       | 6.7         | 63         | 7.9         |
| **Education status**           |              |             |           |             |           |             |
| Less than HS                   | 14,604       | 13.2        | 125       | 6.7\(^a\)   | 93         | 14.6\(^b,c\) |
| HS graduate                    | 25,309       | 25.7        | 315       | 19.4\(^a\)  | 160        | 20.9\(^b\)  |
| College and above              | 58,263       | 61.0        | 1,276     | 74.0\(^a\)  | 538        | 64.5\(^c\)  |
| **Employment status**          |              |             |           |             |           |             |
| Employed                       | 57,091       | 61.1        | 1,183     | 68.2\(^a\)  | 500        | 60.0\(^d\)  |
| Unemployed                     | 4,305        | 4.7         | 111       | 6.1         | 80         | 12.8\(^b,c\) |
| Not in work force              | 37,150       | 34.2        | 423       | 25.7\(^a\)  | 211        | 27.2\(^b\)  |
| **Poverty status\(^d\)**       |              |             |           |             |           |             |
| At or above poverty            | 76,884       | 82.1        | 1,405     | 84.7\(^a\)  | 540        | 73.2\(^b,c\) |
| Below poverty                  | 15,796       | 12.3        | 265       | 12.5        | 220        | 23.3\(^b,c\) |
| Unknown                        | 5,212        | 5.6         | 40        | 2.7\(^a\)   | 25         | 3.5\(^b\)   |
| **Physician contact within past year** |         |             |           |             |           |             |
| ≥1                             | 80,377       | 81.4        | 1,418     | 81.6        | 655        | 82.1        |
| 0                              | 17,903       | 18.6        | 294       | 18.4        | 134        | 17.9        |
| **Has a usual place to go for healthcare** |         |             |           |             |           |             |
| Yes                            | 84,632       | 85.9        | 1,441     | 85.0        | 643        | 79.4\(^b,c\) |
| No                             | 13,926       | 14.1        | 276       | 15.0        | 148        | 20.6        |
| **Has health insurance**       |              |             |           |             |           |             |
| Yes                            | 84,821       | 86.6        | 1,465     | 85.7        | 655        | 82.4\(^b\)  |
| No                             | 13,403       | 13.4        | 241       | 14.3        | 131        | 17.6        |
| **Smoking status**             |              |             |           |             |           |             |
| Current cigarette smoker       | 16,726       | 16.4        | 423       | 22.8\(^a\)  | 225        | 25.4\(^b\)  |
| Former cigarette smoker        | 22,406       | 22.0        | 408       | 22.9        | 163        | 18.6        |
| Never cigarette smoker         | 59,304       | 61.6        | 884       | 54.3\(^a\)  | 403        | 56.0\(^b\)  |
| **Five or more alcoholic drinks in 1 day at least once in past year** |         |             |           |             |           |             |
| Yes                            | 21,641       | 24.8        | 573       | 34.2\(^a\)  | 338        | 42.9\(^b,c\) |
| No                             | 69,121       | 75.2        | 1,034     | 65.8        | 409        | 57.1        |
| **Ever been tested for HIV**   |              |             |           |             |           |             |
| Yes                            | 36,599       | 37.2        | 1,177     | 67.7\(^a\)  | 487        | 58.8\(^b,c\) |
| No                             | 59,702       | 62.8        | 521       | 32.3        | 294        | 41.2        |
| **Self-selected health status**|              |             |           |             |           |             |

(Continued)
coverage among adults aged 18–26 years was 23.5%. Coverage among males and females was 9.5% and 37.9%, respectively. HPV vaccination coverage among bisexual females (51.6%) was significantly higher compared with heterosexual females (40.2%). Overall, HepA vaccination coverage (ever received) among adults aged ≥18 years at high risk for HAV infection was 24.7%, and was significantly higher among gay/lesbian (35.1%) and bisexual (38.0%) compared with heterosexual adults (24.5%). Overall, HepA vaccination coverage among males aged ≥18 years was 25.7%, and was significantly higher among gay males (40.3%) compared with heterosexual males (25.4%). Overall HepA vaccination coverage among females aged ≥18 years was 23.7%, and was significantly higher among bisexual

Table 1. (Continued)

|                          | Heterosexual | Gay/Lesbian | Bisexual |
|--------------------------|--------------|-------------|----------|
|                          | Sample       | Weighted %  | Sample    | Weighted %  | Sample    | Weighted %  |
| Excellent/very good      | 56,902       | 60.8        | 1,068    | 62.1        | 438       | 56.2       |
| Other                    | 41,640       | 39.2        | 650      | 37.9        | 353       | 43.8       |
| **Obesity status**       |              |             |          |             |          |            |
| Yes                      | 28,684       | 29.3        | 495      | 29.5        | 271       | 36.0^c      |
| No                       | 67,207       | 70.7        | 1,200    | 70.5        | 505       | 64.0       |
| **Asthma**               |              |             |          |             |          |            |
| Yes                      | 3,641        | 3.4         | 104      | 5.6^a       | 66        | 7.3^b      |
| No                       | 94,854       | 96.6        | 1,612    | 94.4        | 725       | 92.7       |
| **Diabetes**             |              |             |          |             |          |            |
| Yes                      | 10,467       | 9.4         | 137      | 7.1^a       | 47        | 5.8^b      |
| No                       | 88,065       | 90.6        | 1,580    | 92.9        | 743       | 94.2       |
| **Cardiovascular disease**|             |             |          |             |          |            |
| Yes                      | 12,668       | 11.6        | 184      | 10.5        | 79        | 8.6^b      |
| No                       | 85,786       | 88.4        | 1,533    | 89.5        | 712       | 91.4       |
| **Chronic liver disease**|              |             |          |             |          |            |
| Yes                      | 1,304        | 1.2         | 38       | 1.7         | 21        | 1.9        |
| No                       | 97,188       | 98.8        | 1,677    | 98.3        | 770       | 98.1       |
| **Disability status**    |              |             |          |             |          |            |
| Yes                      | 47,835       | 46.4        | 989      | 55.7^a      | 552       | 69.3^b,c    |
| No                       | 50,747       | 53.6        | 729      | 44.3        | 239       | 30.7       |
| **Met federal guidelines for aerobic physical activity** | | | | | | |
| Yes                      | 8,069        | 8.7         | 137      | 7.9         | 65        | 6.9        |
| No                       | 89,812       | 91.3        | 1,566    | 92.1        | 717       | 93.1       |
| **Travel**               |              |             |          |             |          |            |
| Yes                      | 32,603       | 35.0        | 635      | 37.5        | 270       | 34.1       |
| No                       | 65,882       | 65.0        | 1,082    | 62.5        | 521       | 65.9       |

Note: Boldface indicates significance.

^p<0.05 by t-test for comparisons between heterosexual and gay/lesbian within each level of characteristic.

^p<0.05 by t-test for comparisons between gay/lesbian and bisexual within each level of characteristic.

^p<0.05 by t-test for comparisons between heterosexual and bisexual within each level of characteristic.

Poverty status was defined according to the ratio of a family’s total income to the federal poverty threshold. Federal poverty thresholds are updated annually by the U.S. Census Bureau (https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html).

Persons from developed countries who travel to developing countries with high or intermediate hepatitis A virus [HAV] and hepatitis B virus [HBV] endemicity are considered at substantial risk for acquiring HAV and HBV infections. Persons who traveled outside the United States to countries other than Europe, Japan, Australia, New Zealand, or Canada were considered having traveled to countries with high or intermediate HAV and HBV endemicity.

https://doi.org/10.1371/journal.pone.0213431.1001
Table 2. Unadjusted vaccination coverage of selected vaccines among adults aged ≥18 years in the United States by self-identified sexual orientation–National Health Interview Survey, 2013–2015.

| Sexual Orientation | Human papillomavirus vaccination (≥1 dose) | Hepatitis A vaccination (ever received) | Hepatitis B vaccination (ever received) | Influenza vaccination |
|--------------------|--------------------------------------------|----------------------------------------|----------------------------------------|-----------------------|
| Overall            | n % (95% CI)                               | n % (95% CI)                           | n % (95% CI)                           | n % (95% CI)          |
| Heterosexual       |                                            |                                        |                                        |                       |
| 18–26 years        | 13,065 23.5 (22.3, 24.7)                   | 31,042 24.7 (24.0, 25.4)               | 39,939 35.8 (35.0, 36.5)              | 64,855 43.8 (42.9, 44.7) |
| Male               | 6,267 9.5 (8.4, 10.6)                      | 14,725 25.7 (24.7, 26.8)              | 18,618 32.9 (32.0, 33.9)              | 16,317 23.7 (22.8, 24.6) |
| Female             | 6,798 37.9 (36.0, 39.7)                    | 6,229 40.2 (38.3, 42.2)               | 21,321 38.6 (37.7, 39.5)              | 15,648 23.5 (22.6, 24.5) |
| Gay/Lesbian        |                                            |                                        |                                        |                       |
| 18+ years high-risk | 30,710 24.5 (23.8, 25.2)                   | 587 35.1 (30.7, 39.6)                 | 696 49.8 (44.9, 54.6)                 | 219 48.5 (42.4, 55.0)  |
| Male               | 16,144 24.5 (23.8, 25.2)                   | 52 35.1 (30.7, 39.6)                  | 66 49.8 (44.9, 54.6)                  | 21 48.5 (42.4, 55.0)   |
| Female             | 14,566 40.2 (38.3, 42.2)                   | 57 35.1 (30.7, 39.6)                  | 64 49.8 (44.9, 54.6)                  | 21 48.5 (42.4, 55.0)   |
| Bisexual           |                                            |                                        |                                        |                       |
| 18+ years high-risk | 38,290 35.5 (34.8, 36.2)                   | 696 49.8 (44.9, 54.6)                 | 790 55.1 (47.1, 62.7)                 | 1,074 48.5 (42.4, 55.0) |
| Male               | 17,821 32.6 (31.6, 33.6)                   | 428 52.6 (45.9, 59.3)                 | 187 52.6 (45.9, 59.3)                 | 298 52.6 (45.9, 59.3)  |
| Female             | 20,469 38.4 (37.4, 39.3)                   | 268 45.4 (37.5, 53.6)                 | 85 52.6 (45.9, 59.3)                  | 268 45.4 (37.5, 53.6)  |
| Influenza vaccination |                                            |                                        |                                        |                       |
| 18+ years          | 61,968 43.8 (42.9, 44.7)                   | 1,074 48.5 (42.4, 55.0)               | 1,074 48.5 (42.4, 55.0)               | 1,074 48.5 (42.4, 55.0) |
| Tdap vaccination   |                                            |                                        |                                        |                       |
| 18+ years          | 63,505 20.3 (19.8, 20.9)                   | 1,113 24.2 (21.2, 27.6)               | 1,113 24.2 (21.2, 27.6)               | 1,113 24.2 (21.2, 27.6) |
| Pneumococcal vaccination (ever received) |                                       |                                        |                                        |                       |
| 18–64 years increased risk | 25,973 21.2 (20.5, 21.9)                               | 654 25.2 (20.8, 30.1)                 | 337 21.4 (15.0, 29.6)                 |
| 65+ years          | 23,644 61.7 (60.8, 62.6)                   | 187 63.3 (53.2, 72.4)                 | 52 63.3 (53.2, 72.4)                  |                       |
| Shingles vaccination (ever received) |                                        |                                        |                                        |                       |
| 60+ years          | 31,675 27.8 (26.9, 28.6)                   | 296 30.4 (23.9, 37.9)                 | 84 30.4 (23.9, 37.9)                  |                       |

CI confidence interval.

Note: Boldface indicates significance.

*p<0.05 by t-test (comparing against heterosexual).

*p<0.05 by t-test (comparing against gay/lesbian).

*Estimate is not reported because it is unreliable either due to effective small sample size (n<30) and/or CI half-width >15 as per the National Center for Health Statistics Data Presentation Standards for Proportions, Series 2 Report available at: https://www.cdc.gov/nchs/data/sr/sr02/sr02_175.pdf.

Adults were considered at high-risk for hepatitis A virus (HAV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Adults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Adults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Adults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Adults were considered at high-risk for hepatitis A virus (HAV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Adults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Estimate is not reported because it is unreliable either due to effective small sample size (n<30) and/or CI half-width >15 as per the National Center for Health Statistics Data Presentation Standards for Proportions, Series 2 Report available at: https://www.cdc.gov/nchs/data/sr/sr02/sr02_175.pdf.

Adults were considered at high-risk for hepatitis A virus (HAV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Adults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

Influenza vaccination coverage estimates represent the coverage for an influenza season calculated using the Kaplan-Meier method. The calculation includes respondents vaccinated July 2013 to May 2014 and interviewed August 2013 to June 2014, and July 2014 to May 2015 and interviewed August 2014 to June 2015.

Adults were considered at increased risk for pneumococcal disease if they had ever been told by a doctor or other health professional that they had diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other heart condition; had a diagnosis of cancer during the preceding 12 months (excluding nonmelanoma skin cancer); had ever been told by a doctor or other health professional that they had lymphoma, leukemia, or blood cancer; or they had been told by a doctor or other health professional that they had chronic bronchitis or weak or failing kidneys during the preceding 12 months or had an asthma episode or attack during the preceding 12 months; or they were current smokers.

https://doi.org/10.1371/journal.pone.0213431.t002

females (33.9%) compared with heterosexual females (23.5%). Overall HepB vaccination coverage (ever received) among adults aged ≥18 years at high risk for HBV infection was 35.8%; HepB vaccination coverage among gay/lesbian (49.8%) and bisexual adults (55.1%) was
significantly higher compared with heterosexual adults (35.5%). Overall HepB vaccination coverage among males aged ≥18 years was 32.9% and coverage among gay males (52.6%) was significantly higher than among heterosexual males (32.6%). Overall HepB vaccination coverage among females aged ≥18 years was 38.6% and coverage among bisexual females (58.5%) was significantly higher than among heterosexual females (38.4%) and lesbian females (45.4%). Influenza vaccination coverage overall in the combined 2013–14 and 2014–15 seasons among adults aged ≥18 years was 43.8% and influenza vaccination coverage among bisexual adults (34.1%) was significantly lower compared with heterosexual (43.8%) and gay/lesbian adults (48.5%). Overall Tdap vaccination coverage among adults aged ≥18 years was 20.3% and was significantly higher among gay/lesbian (24.2%) and bisexual (29.8%) compared with heterosexual adults (20.3%). Overall pneumococcal vaccination coverage among adults aged 18–64 years at increased risk for pneumococcal disease was 20.4% and was similar across sexual orientation categories. Pneumococcal vaccination coverage overall among adults aged ≥65 years was 59.2% and was similar across sexual orientation categories. Shingles coverage overall among adults aged ≥60 years was 26.8% and was similar across sexual orientation categories (Table 2).

Adjusted vaccination coverage for each vaccine class is shown in Table 3, overall and stratified by each sexual orientation category. Overall adjusted HepA vaccination coverage among gay/lesbian and bisexual adults was significantly higher compared with heterosexual adults. Adjusted HepA vaccination coverage was significantly higher among gay males compared with heterosexual males. Overall adjusted HepB vaccination coverage among gay/lesbian and bisexual adults was significantly higher compared with heterosexual adults. Adjusted HepB vaccination coverage was significantly higher among gay males compared with heterosexual males. After adjustment, overall influenza vaccination coverage was significantly higher among gay/lesbian compared with heterosexual adults, but significantly lower among bisexual compared with gay/lesbian adults. There were no significant differences by sexual orientation for Tdap, pneumococcal (among adults aged 18–64 years with high-risk conditions and those aged ≥65 years) or shingles vaccination (Table 3).

Table 4 presents the results of the multivariable logistic regression models by selected vaccines. Except for the association of having self-identified as gay/lesbian orientation with greater likelihood of HepA, HepB, and influenza vaccination, sexual orientation was not associated with higher or lower likelihood of vaccination. Health status or other behavioral characteristics studied had no consistent relationship with vaccination among all populations. After controlling for sexual orientation, other characteristics that are generally associated with vaccination were still independently associated with likelihood of vaccination (Table 4).

**Discussion**

Significant differences were observed by sexual orientation for HepA, HepB, and influenza vaccination. Gay/lesbian orientation was associated with a greater likelihood of influenza vaccination. Gay male sexual orientation was associated with greater likelihood of HepA and HepB vaccination.

This study found that HepB vaccination was higher among men who self-identified as gay compared with heterosexual, consistent with findings reported previously [29,46] but lower than reported from studies involving smaller samples of gay males from localized geographical areas and settings [47,48]. Gay/lesbian and bisexual adults also had a higher likelihood of receiving HepA and HepB vaccination. The HepA vaccination coverage observed among gay males (40.3%) in this study was lower than previously reported (69.0%) [48]. Despite recommendations for HepA and HepB vaccination of MSM due to their increased risk for HAV and
Table 3. Adjusted vaccination coverage of selected vaccines among adults aged ≥18 years in the United States by self-identified sexual orientation—National Health Interview Survey, 2013–2015.

|                                   | Sexual Orientation | Prevalence Difference (PD) (adjusted)* |
|-----------------------------------|--------------------|----------------------------------------|
|                                   | Overallb            | Heterosexual                           | Gay or Lesbian                        | Bisexual                           | Gay/Lesbian vs. Heterosexual | Bisexual vs. Gay/ Lesbian | Bisexual vs. Gay/ Lesbian |
|                                   | n                  | % (95% CI)                              | n                                      | % (95% CI)                           | % (95% CI)                       | p-Value                      | p-Value                      | p-Value                      |
| Human papillomavirus vaccination (≥1 dose) |                    |                                       |                                         |                                     |                                    |                              |                              |                              |
| 18–26 years                       | 13,065             | 25.5 (24.2, 26.8)                      | 11,453                                 | 25.2 (23.8, 26.6)                    | 280                               | 27.8 (20.7, 36.2)             | 226                           | 39.8 (32.1, 48.2)             | 2.6 (-5.4, 10.6)             | 0.523 | 14.7 (6.4, 22.9)*             | <0.001 | 12.1 (0.6, 23.9)*             | 0.040 |
| Male                              | 6,267              | 10.3 (9.2, 11.7)                       | 5,500                                  | 10.1 (8.9, 11.5)                     | 136                               | 16.0 (9.5, 25.8)              | 58                            | 18.6 (8.4, 36.4)              | 5.9 (-2.2, 14.0)             | 0.153 | 8.5 (-5.3, 22.3)              | 0.229 | NR*                          | -     |
| Female                            | 6,798              | 41.0 (39.0, 43.1)                      | 5,953                                  | 40.6 (38.6, 42.8)                    | 144                               | 45.4 (33.8, 57.6)             | 168                           | 50.8 (40.4, 61.1)             | 4.8 (-7.5, 17.0)             | 0.446 | 10.1 (-6.6, 20.8)             | 0.065 | NR*                          | -     |
| Hepatitis A vaccination (ever received) |                    |                                       |                                         |                                     |                                    |                              |                              |                              |
| 18+ years high-riskc              | 31,042             | 24.9 (24.1, 25.7)                      | 29,710                                 | 24.7 (23.9, 25.5)                    | 587                               | 30.9 (27.0, 35.2)             | 245                           | 32.8 (26.0, 40.4)             | 6.2 (2.1, 10.3)*             | 0.003 | 8.1 (0.9, 15.3)*              | 0.03  | 1.9 (-6.3, 10.1)              | 0.655 |
| 18+ years high-risk, male         | 15,342             | 25.7 (24.6, 26.8)                      | 14,062                                 | 25.6 (24.5, 26.7)                    | 368                               | 32.6 (27.1, 38.6)             | 70                            | NR*                          | 6.9 (1.2, 12.7)*             | 0.02  | NR*                          | -     | NR*                          | -     |
| 18+ years high-risk, female        | 17,132             | 23.6 (22.6, 24.6)                      | 15,648                                 | 23.8 (22.8, 24.8)                    | 219                               | 27.1 (20.0, 35.6)             | 175                           | 28.9 (21.2, 37.9)             | 3.3 (-4.6, 11.2)             | 0.417 | 5.1 (-3.4, 13.5)              | 0.239 | 1.8 (-8.8, 12.4)              | 0.742 |
| Hepatitis B vaccination (ever received) |                    |                                       |                                         |                                     |                                    |                              |                              |                              |
| 18+ years high-riskd              | 39,939             | 36.4 (35.6, 37.2)                      | 38,290                                 | 36.2 (35.4, 37.0)                    | 696                               | 43.6 (38.9, 48.5)             | 290                           | 44.0 (36.7, 51.6)             | 7.4 (2.6, 12.3)*             | 0.003 | 7.8 (0.3, 15.2)*              | 0.042 | 0.3 (-8.6, 9.3)               | 0.939 |
| 18+ years high-risk, male         | 19,204             | 33.7 (32.7, 34.8)                      | 17,821                                 | 33.3 (32.3, 34.4)                    | 428                               | 44.5 (38.4, 50.8)             | 85                            | NR*                          | 11.2 (4.9, 17.5)*             | <0.001 | NR*                          | -     | NR*                          | -     |
| 18+ years high-risk, female        | 22,105             | 39.3 (38.3, 40.3)                      | 20,469                                 | 39.1 (38.1, 40.2)                    | 268                               | 40.1 (32.3, 48.3)             | 205                           | 47.2 (38.0, 56.7)             | 0.9 (-7.1, 8.9)              | 0.821 | 8.1 (-1.4, 17.6)              | 0.096 | 7.2 (-5.5, 19.8)              | 0.266 |
| Influenza vaccination              |                    |                                       |                                         |                                     |                                    |                              |                              |                              |
| 18+ years                         | 64,855             | 42.0 (41.3, 42.8)                      | 61,968                                 | 42.0 (41.2, 42.8)                    | 1,074                             | 48.1 (44.2, 52.0)             | 512                           | 37.1 (30.7, 43.9)             | 6.1 (2.3, 10.0)*             | 0.002 | -4.9 (-11.5, 1.8)             | 0.150 | -11.0 (-18.3, -3.7)*         | 0.003 |
| Tdap vaccination                  |                    |                                       |                                         |                                     |                                    |                              |                              |                              |
| 18+ years                         | 66,380             | 20.9 (20.4, 21.5)                      | 63,505                                 | 20.9 (20.3, 21.5)                    | 1,113                             | 20.7 (17.9, 23.9)             | 525                           | 25.3 (20.4, 30.9)             | -0.2 (-3.1, 2.8)             | 0.916 | 4.4 (-0.8, 9.6)               | 0.101 | 4.6 (-1.3, 10.4)              | 0.127 |
| Pneumococcal vaccination (ever received) |                    |                                       |                                         |                                     |                                    |                              |                              |                              |
| 18–64 years increased riskb       | 28,000             | 20.8 (20.1, 21.6)                      | 25,973                                 | 20.7 (20.0, 21.5)                    | 654                               | 24.2 (20.2, 28.6)             | 337                           | 22.5 (16.8, 29.5)             | 3.5 (-0.8, 7.7)              | 0.110 | 1.8 (-4.7, 8.2)               | 0.591 | -1.7 (-9.0, 5.6)              | 0.649 |
| 65+ years                         | 24,754             | 61.8 (60.8, 62.8)                      | 23,644                                 | 61.8 (60.8, 62.8)                    | 187                               | 58.5 (48.9, 67.5)             | 52                            | NR*                          | -3.3 (-12.7, 6.1)             | 0.492 | NR*                          | -     | NR*                          | -     |

(Continued)
### Table 3. (Continued)

| Sexual Orientation | Prevalence Difference (PD) (adjusted)* |
|--------------------|----------------------------------------|
|                    | Overall8 | Heterosexual | Gay or Lesbian | Bisexual | Gay/Lesbian vs. Heterosexual | Bisexual vs. Heterosexual | Bisexual vs. Gay/ Lesbian |
|                    | n (95% CI) | n (95% CI) | n (95% CI) | n (95% CI) | p-Value | p-Value | p-Value |
| Shingles vaccination (ever received) | | | | | | | |
| 60+ years          | 33,271 (28.5, 29.5) | 31,675 (28.5, 29.5) | 296 (25.8, 32.7) | 84 | NR8 | -2.7 (-9.1, 3.7) | 0.413 | NR8 | - | NR8 |

CI confidence interval.

**Note:** Boldface indicates significance.

*Adjusted estimates control for age, sex, race/ethnicity, education, employment status, poverty status, physician contact within the past year, usual place of healthcare, health insurance status, self-reported smoking status, five or more alcoholic drinks in 1 day at least once in past year, HIV test status, self-reported health status, obesity status, asthma status, diabetes status, cardiovascular disease status, chronic liver disease status, disability status, and met Federal guidelines for aerobic physical activity, and in addition, travel for hepatitis A and hepatitis B vaccination.

*In addition to all other noted adjustment factors, overall estimates also controlled for self-reported sexual orientation.

*p* < 0.05 by t-test (comparing against heterosexual).

*p* < 0.05 by t-test (comparing against gay/lesbian).

*Estimate is not reported because it is unreliable either due to effective small sample size (n < 30) and/or CI half-width > 15 as per the National Center for Health Statistics Data Presentation Standards for Proportions, Series 2 Report available at: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.

*Adults were considered at high-risk for hepatitis A virus (HAV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor; or other health professional that they had any kind of chronic, or long-term liver condition.

*Adults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: if they had ever been told by a doctor or other health professional that they had diabetes; ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995; or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition.

*Adults were considered at increased risk for pneumococcal disease if they had ever been told by a doctor or other health professional that they had diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other heart condition; had a diagnosis of cancer during the previous 12 months (excluding nonmelanoma skin cancer); had ever been told by a doctor or other health professional that they had lymphoma, leukemia, or blood cancer; or they had been told by a doctor or other health professional that they had chronic bronchitis or weak or failing kidneys during the preceding 12 months or had an asthma episode or attack during the preceding 12 months; or they were current smokers.

https://doi.org/10.1371/journal.pone.0213431.t003

### Table 4. Multivariable logistic regression analysis among persons aged ≥18 years in the United States who reported receiving selected vaccines by self-identified sexual orientation, demographic characteristics, health conditions, health behaviors, and healthcare access—National Health Interview Survey, 2013–2015.

| Vaccination (ever received) | Human Papillomavirus Vaccination (≥1 dose) | Hepatitis A Vaccination (ever received) | Hepatitis B Vaccination (ever received) | Influenza Vaccination | Tdap Vaccination | Shingles Vaccination (ever received) | Pneumococcal Vaccination (ever received) |
|----------------------------|--------------------------------------------|---------------------------------------|----------------------------------------|-----------------------|----------------|--------------------------------------|------------------------------------------|
| 18–26 years                | 18 and over high-risk8 (n = 31,042)         | 18 and over high-risk8 (n = 39,939)    | 18 and over (n = 64,855)               | 18 and over (n = 66,380) | 60 and over (n = 33,271) | 18–64 increased risk8 (n = 28,000) | 65 and over (n = 24,754) |
| APD8                       | APD8                                      | APD8                                 | APD8                                  | APD8                  | APD8          | APD8                                | APD8                                    |
| (95% CI)                   | (95% CI)                                  | (95% CI)                              | (95% CI)                              | (95% CI)              | (95% CI)     | (95% CI)                             | (95% CI)                                |

**Sexual Orientation**

|                | Heterosexual  | Gay/lesbian | Bisexual   |       |
|----------------|---------------|-------------|------------|------|
|                | Referent      | Referent    | Referent   |      |
| Heterosexual   | Referent      | Referent    | Referent   |      |
| Gay/lesbian    | 5.9 (-1.4, 13.2) | 6.2 (2.1, 10.3) | 7.4 (2.6, 12.3) | 6.1 (2.2, 10.0) | 0.413 | NR8 | -3.3 (-12.7, 6.1) |
| Bisexual       | 7.0 (-0.2, 14.2) | 8.1 (0.9, 15.3) | 7.8 (0.3, 15.2) | 5.0 (-11.6, 1.7) | 4.4 (-0.8, 9.6) | NR8 | 1.8 (-4.7, 8.2) |
| Age group (years) | 18–49 | Referent | Referent | NA | Referent | NA |

(Continued)
### Table 4. (Continued)

| Human Papillomavirus Vaccination (<1 dose) | Hepatitis A Vaccination (ever received) | Hepatitis B Vaccination (ever received) | Influenza Vaccination | Tdap Vaccination | Shingles Vaccination (ever received) | Pneumococcal Vaccination (ever received) |
|------------------------------------------|---------------------------------------|----------------------------------------|-----------------------|-----------------|--------------------------------------|-----------------------------------------|
| 18–26 years (n = 13,065)                 | 18 and over high-risk (n = 31,042)    | 18 and over high-risk (n = 39,939)     | 18 and over (n = 64,855) | 18 and over (n = 66,380) | 60 and over (n = 33,271) | 18–64 increased risk (n = 28,000) |
| 50–64                                   | -10.1 (-11.7, -8.5)                   | -12.3 (-14.1, -10.5)                  | 9.6 (8.1, 11.1)        | NA               | NA                                   | 9.6 (8.1, 11.1)                         |
| 65 and over                              | NA                                    | -12.9 (-15.3, -10.6)                  | -22.5 (-24.5, -20.4)   | 26.2 (24.2, 28.2) | NA                                   | NA                                     |
| 18–21                                   | Referent                              | NA                                     | NA                    | NA               | NA                                   | NA                                     |
| 22–26                                   | -11.1 (-13.7, -8.6)                   | NA                                     | NA                    | NA               | NA                                   | NA                                     |
| 18–24                                   | NA                                    | NA                                     | Referent              | NA               | NA                                   | NA                                     |
| 25–34                                   | NA                                    | NA                                     | NA                    | -4.6 (-6.7, -2.4) | NA                                   | NA                                     |
| 35–44                                   | NA                                    | NA                                     | NA                    | -10.4 (-12.7, -8.1) | NA                                   | NA                                     |
| 45–64                                   | NA                                    | NA                                     | NA                    | -49.1 (-51.3, -46.9) | NA                                   | NA                                     |
| 65 and over                              | NA                                    | NA                                     | NA                    | -45.5 (-47.7, -43.3) | NA                                   | NA                                     |
| 60–64                                   | NA                                    | NA                                     | NA                    | NA               | Referent                             | NA                                     |
| 65–74                                   | NA                                    | NA                                     | NA                    | 10.5 (8.6, 12.5) | NA                                   | Referent                              |
| 75–84                                   | NA                                    | NA                                     | NA                    | 9.0 (6.8, 11.1) | NA                                   | 8.5 (6.3, 10.6)                         |
| 85 and over                              | NA                                    | NA                                     | NA                    | -49.8 (-52.7, -46.9) | NA                                   | 10.0 (7.1, 13.0)                         |
| **Sex**                                 |                                        |                                        |                       |                  |                                       |                                         |
| Male                                    | Referent                              | NA                                     | Referent              | Referent         | Referent                             | Referent                               |
| Female                                  | 28.1 (25.6, 30.5)                     | -3.3 (-4.7, -1.8)                     | 5.3 (4.0, 6.6)        | 3.7 (2.6, 4.7)  | 1.2 (0.1, 2.2)                       | 4.7 (3.2, 6.3)                         |
| **Race/ethnicity**                      |                                        |                                        |                       |                  |                                       |                                         |
| Non-Hispanic white                      | Referent                              | Referent                              | Referent              | Referent         | Referent                             | Referent                               |
| Non-Hispanic black                      | -3.9 (-7.3, -0.6)                     | -3.3 (-6.1, -0.5)                     | -3.1 (-5.6, -0.7)     | -7.3 (-8.9, -5.6) | -10.3 (-11.7, -9.0)              | -17.3 (-19.4, -15.1)                  |
| Hispanic                                | -2.0 (-4.6, 0.6)                      | -4.2 (-6.2, -2.1)                     | -5.1 (-7.0, -3.2)     | -4.0 (-5.8, -2.1) | -8.4 (-9.8, -7.0)                  | -12.6 (-15.2, -10.0)                  |
| Non-Hispanic other, multiple races      | -2.3 (-6.1, 1.4)                      | 2.1 (-0.2, 4.5)                      | 2.6 (0.4, 4.8)        | 2.3 (0.3, 4.3)  | -4.1 (-6.1, -2.2)                  | -8.0 (-11.0, -4.9)                    |
| **Education status**                    |                                        |                                        |                       |                  |                                       |                                         |
| Less than HS                            | Referent                              | Referent                              | Referent              | Referent         | Referent                             | Referent                               |
| HS graduate                             | -0.1 (-3.8, 3.6)                      | 2.2 (-0.8, 5.3)                      | 2.5 (-0.4, 5.4)       | -1.4 (-3.4, 0.7) | 0.8 (-0.9, 2.4)                     | 6.0 (3.8, 8.3)                         |
| College and above                       | 5.6 (2.0, 9.1)                        | 10.6 (7.7, 13.5)                     | 14.4 (11.6,17.1)      | 4.7 (2.8, 6.5)  | 8.2 (6.6, 9.8)                      | 14.0 (11.9, 16.2)                     |
| **Employment status**                   |                                        |                                        |                       |                  |                                       |                                         |
| Employed                                | Referent                              | Referent                              | Referent              | Referent         | Referent                             | Referent                               |
| Unemployed                              | -0.8 (-4.6, 3.0)                      | 3.2 (-0.4, 6.8)                      | 1.3 (-2.1, 4.8)       | -5.1 (-8.2, -2.1) | -1.2 (-3.5, 1.0)                  | -12.3 (-17.6, -6.9)                  |
| Not in work force                       | -1.7 (-4.6, 1.2)                      | 5.0 (3.0, 7.0)                       | -0.4 (-2.2, 1.4)      | 2.0 (0.4, 3.5)  | 0.9 (-0.4, 2.2)                     | 3.5 (1.8, 5.1)                         |
| **Poverty status**                      |                                        |                                        |                       |                  |                                       |                                         |
| Below poverty                           | Referent                              | Referent                              | Referent              | Referent         | Referent                             | Referent                               |
| At or above poverty                     | -1.1 (-4.0, 1.7)                      | -4.0 (-6.8, -1.2)                    | -3.1 (-5.5, -0.6)     | 4.1 (2.4, 5.8)  | 3.6 (2.2, 5.1)                      | 8.1 (5.7, 10.5)                        |
| Unknown                                 | -4.9 (-11.1, 1.3)                     | -6.3 (-10.7, -2.0)                   | -4.4 (-8.4, -0.4)     | 1.7 (-1.5, 4.8)  | -2.0 (-4.4, 0.5)                  | 5.1 (1.4, 8.7)                         |

(Continued)
Table 4. (Continued)

| Vaccination differences by self-identified sexual orientation among U.S. adults |
|--------------------------------------------------|
| Human Papillomavirus Vaccination (≥1 dose) | Hepatitis A Vaccination (ever received) | Hepatitis B Vaccination (ever received) | Influenza Vaccination | Tdap Vaccination | Shingles Vaccination (ever received) | Pneumococcal Vaccination (ever received) |
|-----------------------------------------------|----------------------------------------|----------------------------------------|----------------------|-----------------|-------------------------------------|------------------------------------------|
| 18–26 years (n = 13,065)                      | 18 and over high-risk (n = 31,042)     | 18 and over high-risk (n = 39,939)     | 18 and over (n = 64,855) | 18 and over (n = 66,380) | 60 and over (n = 33,271) | 18–64 increased risk (n = 28,000) |
| APD * (95% CI)                                | APD * (95% CI)                         | APD * (95% CI)                         | APD * (95% CI)        | APD * (95% CI)   | APD * (95% CI)                     | APD * (95% CI)                           |
| Physician contact within past year             |                                        |                                        |                      |                 |                                    |                                          |
| 0 Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| ≥1                                            | 7.8 (5.2, 10.5)                        | 4.7 (3.0, 6.4)                         | 4.6 (2.8, 6.4)       | 16.0 (14.3, 17.7) | 8.7 (7.6, 9.9)                      | 13.8 (11.4, 16.2)                       |
| Has a usual place to go for healthcare         |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 3.6 (1.1, 6.2)                         | -2.7 (-4.9, -0.5)                      | -2.5 (-4.7, -0.3)    | 10.3 (8.4, 12.2) | 4.3 (2.8, 5.8)                      | 12.1 (8.3, 15.9)                       |
| Has health insurance                           |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 10.4 (7.5, 13.2)                       | 2.5 (-0.0, 5.0)                        | 5.8 (3.4, 8.3)       | 13.2 (11.3, 15.0) | 5.2 (3.8, 6.7)                      | 8.6 (2.7, 14.5)                        |
| Smoking status                                 |                                        |                                        |                      |                 |                                    |                                          |
| Never smoker Referent                          | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Current smoker                                | 1.6 (-2.0, 5.2)                        | -2.0 (-4.3, 0.3)                       | -3.5 (-5.8, -1.1)    | -8.8 (-10.5, -7.1) | -2.8 (-4.2, -1.5)                   | -7.8 (-10.5, -5.2)                     |
| Former smoker                                 | -2.7 (-6.7, 1.2)                       | -2.3 (-4.0, -0.6)                      | -2.8 (-4.5, -1.1)    | 1.3 (-0.2, 2.7)  | -0.7 (-1.9, 0.4)                    | 1.5 (-0.1, 3.1)                        |
| Five or more alcoholic drinks in 1 day at least once in past year |                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 2.8 (-1.5, 7.2)                        | 0.4 (-2.0, 2.7)                        | 0.4 (-1.8, 2.7)      | -3.8 (-5.6, -2.0) | 1.7 (0.2, 3.3)                      | 2.4 (-0.6, 5.4)                        |
| Ever been tested for HIV                       |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 5.7 (3.2, 8.1)                         | 10.2 (8.8, 11.7)                       | 13.0 (11.4, 14.5)    | 4.0 (2.8, 5.2)  | 7.4 (6.4, 8.4)                      | 3.9 (1.7, 6.0)                        |
| Self-selected health status                    |                                        |                                        |                      |                 |                                    |                                          |
| Other Referent                                 | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Excellent/ good                                | 1.2 (-1.2, 3.6)                        | 2.8 (1.3, 4.3)                         | 2.0 (0.4, 3.5)       | -0.7 (-2.1, 0.6) | 2.8 (1.7, 3.9)                      | 4.4 (2.8, 6.1)                        |
| Obesity status                                 |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | -3.2 (-6.1, -0.4)                      | -2.5 (-4.3, -0.8)                      | -0.8 (-2.3, 0.8)     | 1.0 (-0.4, 2.3) | 1.8 (0.7, 2.9)                      | 0.4 (-1.2, 1.9)                       |
| Asthma                                         |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 2.6 (-2.5, 7.6)                        | 1.6 (-2.3, 5.6)                        | 3.2 (-0.3, 6.7)      | 2.4 (-0.7, 5.4) | 6.6 (4.1, 9.1)                      | 1.6 (-2.4, 5.6)                       |
| Diabetes                                       |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | -0.8 (-11.0, 9.4)                      | -1.1 (-3.7, 1.5)                       | -0.5 (-3.6, 2.7)     | 6.9 (5.0, 8.9)  | -0.5 (-2.2, 1.3)                    | -1.2 (-3.1, 0.7)                       |
| Cardiovascular disease                         |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 0.0 (-5.4, 5.4)                        | 0.8 (-2.0, 3.5)                        | 1.8 (-0.6, 4.2)      | 3.5 (1.7, 5.3)  | 2.0 (0.3, 3.6)                      | -0.4 (-2.0, 1.1)                      |
| Chronic liver disease                          |                                        |                                        |                      |                 |                                    |                                          |
| No Referent                                    | Referent                               | Referent                               | Referent             | Referent        | Referent                            | Referent                                 |
| Yes                                           | 3.3 (1.6, 4.9)                         | 8.5 (6.4, 10.6)                        | (Continued)           |                 |                                    |                                          |
Table 4. (Continued)

| Vaccination Differences | Human Papillomavirus Vaccination (ever received) | Hepatitis A Vaccination (ever received) | Hepatitis B Vaccination (ever received) | Influenza Vaccination (ever received) | Tdap Vaccination (ever received) | Shingles Vaccination (ever received) | Pneumococcal Vaccination (ever received) |
|-------------------------|-------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|----------------------------------|------------------------------------------|
| Age                     | 18–26 years (n = 13,065)                        | 18 and over high-risk (n = 31,042)    | 18 and over high-risk (n = 39,939)    | 18 and over (n = 64,855)       | 18 and over (n = 66,380)       | 60 and over (n = 33,271)      | 18–64 increased risk (n = 28,000) |
| No                      | Referent                                        | Referent                              | Referent                              | Referent                        | Referent                        | Referent                        | Referent                                |
| Yes                     | NR **                                           | 0.5 (-6.4, 7.4)                       | 8.4 (3.4, 13.4)                       | 5.4 (0.4, 10.4)                 | 1.4 (-2.5, 5.3)                 | 0.3 (-5.9, 6.5)                 | 7.1 (3.2, 11.1)                      |

Disability status

| Vaccination Differences | Met federal guidelines for aerobic physical activity | Travel |
|-------------------------|--------------------------------------------------|---------|
| Age                     | 0-18 years high-risk                              |         |
| No                      | Referent                                        | Referent|
| Yes                     | 3.4 (-1.0, 7.8)                                  |         |

CI confidence interval; NA not applicable.

Note: Boldface indicates significance (p < 0.05 comparing to reference group).

aAdults were considered at high-risk for hepatitis A virus (HAV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995 or if they had been ever told by a doctor; or other health professional that they had any kind of chronic, or long-term liver condition.

bAdults were considered at high-risk for hepatitis B virus (HBV) infection if they reported any one of the following risk factors: ever traveled outside of the United States to countries other than Europe, Japan, Australia, New Zealand or Canada, since 1995; or if they had been ever told by a doctor or other health professional that they had any kind of chronic, or long-term liver condition; or if they had ever been told by a doctor or other health professional that they had diabetes.

\( ^{c} \text{Adults were considered at increased risk for pneumococcal disease if they had ever been told by a doctor or other health professional that they had diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other heart condition; had a diagnosis of cancer during the previous 12 months (excluding nonmelanoma skin cancer); had ever been told by a doctor or other health professional that they had lymphoma, leukemia, or blood cancer; or they had been told by a doctor or other health professional that they had chronic bronchitis or weak or failing kidneys during the preceding 12 months or had an asthma episode or attack during the preceding 12 months; or they were current smokers.} \)

\( ^{d} \text{Adjusted prevalence differences, adjusted for age, sex, race/ethnicity, education, employment status, poverty status, physician contact within the past year, usual place of healthcare, health insurance status, self-reported smoking status, five or more alcoholic drinks in 1 day at least once in past year, HIV test status, self-reported health status, obesity status, asthma status, diabetes status, cardiovascular disease status, chronic liver disease status, disability status, met Federal guidelines for aerobic physical activity, and sexual orientation.} \)

\( ^{e} \text{Adjusted prevalence differences, adjusted for age, sex, race/ethnicity, education, employment status, poverty status, physician contact within the past year, usual place of healthcare, health insurance status, self-reported smoking status, five or more alcoholic drinks in 1 day at least once in past year, HIV test status, self-reported health status, obesity status, asthma status, diabetes status, cardiovascular disease status, chronic liver disease status, disability status, met Federal guidelines for aerobic physical activity, sexual orientation, and travel.} \)

\( ^{f} \text{Estimate is not reported because it is unreliable either due to effective small sample size (n<30) and/or CI half-width >15 as per the National Center for Health Statistics Data Presentation Standards for Proportions, Series 2 Report available at: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.} \)

\( ^{g} \text{Poverty status was defined according to the ratio of a family’s total income to the federal poverty threshold. Federal poverty thresholds are updated annually by the U.S. Census Bureau (https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html).} \)

\( ^{h} \text{Persons from developed countries who travel to developing countries with high or intermediate HAV and HBV endemicity are considered at substantial risk for acquiring HAV and HBV infections. Persons who traveled outside the United States to countries other than Europe, Japan, Australia, New Zealand, or Canada were considered having traveled to countries with high or intermediate HAV and HBV endemicity.} \)

https://doi.org/10.1371/journal.pone.0213431.1004
HBV infection [3,5], many gay males and bisexual males have not been vaccinated. More gay men than bisexual men have been reported to disclose to their primary care providers about their sexual encounters with men [29], thus may provide healthcare providers more opportunity to recognize the need for and recommend HepA and HepB vaccination to gay men. This may help explain the observed higher HepA and HepB vaccination coverage in this population. Having self-identified as gay/lesbian orientation was associated with greater likelihood of influenza vaccination in our multivariable analysis, with bisexual adults having lower influenza coverage than gay/lesbian and heterosexual adults. That bisexual adults were less likely to have health insurance or a usual place for health care, and more likely to be below poverty in this study might be contributors to this finding.

Because HepA, HepB, and HPV vaccinations protect against sexually transmitted infections, persons at higher risk of acquiring these infections because of risky sexual behaviors (e.g., MSM) might be expected to have higher coverage for those vaccines. Though HepA and HepB vaccination coverage among gay males and bisexual females was significantly higher than heterosexual males, HepA and HepB vaccination coverage among high-risk adults remains suboptimal and most remain at risk for HAV and HBV infection. As new HBV infections continue to occur with cumulative exposure over time and transmission among MSM continues during adulthood [49], until the vaccinated young adults age, which over time may increase the vaccine-induced population immunity, “catch-up” HepA and HepB vaccination campaigns among the unvaccinated, at-risk young adult population [3,5] might help improve coverage. Additional strategies to improve HepA and HepB vaccination among adults at increased risk might include: encouraging healthcare providers to identify candidates for HepA and HepB vaccination and ensuring that all adults at risk for HAV and HBV infection or who seek protection from HAV and HBV infection are offered HepA and HepB vaccines [3,5,50]; healthcare providers providing environments that facilitate both gay and bisexual men disclosing their sexual behaviors and other risk factors, possibly by posting non-discrimination statements in their clinics, encouraging openness in patient-provider discussions, using gender-neutral language about sexual partners, and discussing sexual health issues openly using nonjudgmental questions about sexual practices and behaviors [51–53]; and routine provision of HepB vaccine possibly at settings serving gender minorities, such as HIV counseling and testing sites that are able to provide vaccination.

This study used multivariable logistic model(s) to identify factors associated with vaccination. For HepA and HepB vaccinations, the findings from the multivariable models were driven mainly by males. A significantly higher percentage of gay men had received HepA and/ or HepB vaccinations than their heterosexual counterparts, possibly reflecting differential implementation of recommendations for vaccination of individuals at increased risk due to sexual behavior versus travel to countries in which HAV or HBV are endemic or having diabetes or chronic liver disease [2], differential recall of vaccination by the at risk population, as well as additional unmeasured confounding factor(s). A significantly higher percentage of gay/lesbian adults had received influenza vaccination than heterosexual adults, but not Tdap, pneumococcal or shingles vaccination. This observation is not well understood given the greater use of health services among gay/lesbian adults and the generally higher acceptability of vaccines in these groups [29]. In the multivariable models, however, no specific causal model or hypothesis was posed for the relationship between vaccination (for each specific vaccine) and the demographic, behavioral, health status, access to care characteristics, and sexual orientation considered in this report. Thus, although multiple factors were identified as having an independent association with a higher or lower likelihood of vaccination, the relative importance of these factors with respect to their association with vaccination cannot be determined from this analysis. The models were successful, however, in identifying factors generally
associated with vaccination. Similar to other reports, characteristics associated with greater likelihood of vaccination included higher education, having health insurance, having had at least one or more physician contacts within the past year, and having a usual place to go for healthcare, even when controlling for sexual orientation [46,48].

Overall self-identified sexual orientation estimates from this report were similar to that reported from state-level and national surveys [17,18,54]. The estimates found in this report were lower compared with sexual orientation estimates reported elsewhere [55–57]. The differences in point estimates might be due to differences in sampling design, mode of the surveys, or other survey attributes. With the inclusion of questions on sexual orientation for the first time in the NHIS in 2013, it became possible to examine differences in self-reported receipt of selected vaccines by self-reported sexual orientation in a sample of U.S. adults from a national probability-based survey. Further, we also observed other important differences in respondent characteristics by sexual orientation, similar to those previously reported [1,2,15–19,31,52–54,58–60].

Several limitations should be considered in interpreting the results of this study. First, the information on vaccination was self-reported and may be subject to recall bias. However, adult self-reported vaccination status has been shown to be ≥70% sensitive in one or more studies for influenza, pneumococcal, tetanus toxoid-containing, herpes zoster, and HepB vaccines and ≥70% specific in one or more studies for all except tetanus and HepB vaccination [61–65]. Second, adult HepA and HepB vaccination are recommended for all unvaccinated adults at risk for HAV and HBV infection and for all adults requesting protection from HAV and HBV infection with the acknowledgment that a specific risk factor should not be a requirement for vaccination [3,5]. Because the NHIS does not collect information on all risk conditions for HAV and HBV infections, we were unable to identify all adults who were at increased risk for HAV and HBV infection and report vaccination estimates for these groups. Also, as the NHIS does not include measurement tools to assess whether or not prevention methods were used by the study sample while engaging in risky sexual behaviors, we could not conduct additional analysis for HepA and HepB vaccination by stratifying on adults self-identifying as gay/lesbian or bisexual that practiced sexual behaviors that put them at high risk for HAV and HBV infection. Third, the response rates for the three survey years in the report were 61.2%, 58.9%, and 55.2%. Nonresponse bias can result if respondents and nonrespondents differ in their vaccination rates and rates of other characteristics. Fourth, the differences observed in findings across studies could be a result of the differences in survey design, the mode of the surveys, question wording between NHIS and other data sources, and possible differential nonresponse by sexual orientation. Fifth, respondents with responses of “something else” (0.2%), “I don’t know the answer” (0.5%), and refused (0.5%) for the sexual orientation questions were classified as missing and excluded from the analyses. Although a small proportion of the overall sample, these exclusions create a small potential for bias and prevent assessment of the health indices and vaccination status of less populous groups (e.g., persons who identify as transgender). Sixth, the Tdap estimate is subject to considerable uncertainty. Respondents who reported a tetanus vaccination but were unable to say whether Td or Tdap was used during 2005–2015 were excluded from estimations of Tdap coverage (36.7%), creating a potential for bias. Seventh, despite combining three years of data for a larger sample size, the number of adults self-identifying as gay/lesbian, or bisexual was still relatively small when stratified across multiple covariate categories, which might cause some estimates to be unstable. The results pertaining to gay/lesbian or bisexual groups should be interpreted with caution. As additional years of data become available, more stable estimates could be generated. Eighth, the NHIS is a general population survey. The weighting is intended to represent the general population, not specifically populations defined by sexual orientation. Therefore, the estimates among gay, lesbian or
bisexual respondents in this study might not be generalizable to the entire gay, lesbian or bisexual population [56,57]. Additionally, as noted, the sample size of persons in the NHIS who identified as gay, lesbian or bisexual is relatively small, which limited the ability to report coverage estimates by individual survey years. Ninth, as there are no unique personal identifiers in the NHIS that would allow determination of the proportion of respondents that might be survey repeaters across the years included in this study, it would be difficult to know if participants from each year were unique from other years. When the sociodemographic and health-related factors of the survey respondents from individual years (2013 vs. 2014, 2013 vs. 2015, 2014 vs. 2015 [data not shown]) were compared, similar patterns of similarity and differences were observed across the years, suggesting participants from each were unique from other years. Finally, though we controlled for potential confounders in this study, there might be unknown confounders that were not controlled for that might have biased the study estimates, the extent of which is hard to estimate.

Despite these limitations, study strengths include findings from a national probability-based survey that included noninstitutionalized U.S. adults who self-identified as gay/lesbian and bisexual that allowed national level vaccination coverage estimation by sexual orientation. This study is the first to assess associations of sexual orientation with a comprehensive list of vaccinations and could serve as a baseline for monitoring vaccination coverage changes over time.

Conclusions
This study helps document differences in self-reported vaccination coverage by self-identified sexual orientation among U.S. adults aged 18 years and over and is the first to assess associations of sexual orientation with a comprehensive list of vaccinations. Findings from this study can serve as a baseline for monitoring vaccination coverage changes over time, and can assist the development of targeted strategies to improve the health status of lesbian, gay, and bisexual populations. Annual data on sexual orientation from the NHIS can be useful in monitoring the impact of policies and interventions directed at improving the health of those who identify as gay, lesbian and bisexual.

Acknowledgments
The authors thank James M. Dahlhamer and Stacie M. Greby for their thoughtful review of the manuscript.

Author Contributions
Conceptualization: Anup Srivastav.
Data curation: Anup Srivastav.
Formal analysis: Anup Srivastav, Alissa O’Halloran.
Investigation: Anup Srivastav, Alissa O’Halloran, Peng-Jun Lu, Walter W. Williams, Sonja S. Hutchins.
Methodology: Anup Srivastav.
Project administration: Anup Srivastav, Walter W. Williams.
Resources: Anup Srivastav, Alissa O’Halloran, Peng-Jun Lu, Walter W. Williams.
Supervision: Anup Srivastav, Walter W. Williams.
**Validation:** Anup Srivastav, Alissa O’Halloran, Peng-Jun Lu, Walter W. Williams, Sonja S. Hutchins.

**Writing – original draft:** Anup Srivastav.

**Writing – review & editing:** Anup Srivastav, Alissa O’Halloran, Peng-Jun Lu, Walter W. Williams, Sonja S. Hutchins.

**References**

1. Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(4):88–90. https://doi.org/10.15585/mmwr.mm6504a5 PMID: 26845417

2. Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016; 164(3):184–194. https://doi.org/10.7326/M15-3005 PMID: 26829913

3. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16):1–33. PMID: 17159833.

4. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis RC, Gee J, et al; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014; 63(RR05):1–30. PMID: 25167164.

5. Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-7):1–23. PMID: 16708058.

6. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Mortal Wkly Rep 2014; 63:822–5. PMID: 2533284

7. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(No. RR-5):1–30.

8. Advisory Committee on Immunization Practices (ACIP), Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR08):1–62. PMID: 20689501.

9. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008; 57(No. RR-5). PMID: 18528318.

10. Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I, Lee GM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006; 55(RR-17):1–37. PMID: 17167397

11. Fredriksen-Goldsen KI, Kim HJ, Barkan SE, Muraco A, Hoy-Ellis CP. Health disparities among lesbian, gay, and bisexual older adults: results from a population-based study. Am J Public Health. 2013; 103(10):1802–1809. https://doi.org/10.2105/AJPH.2012.301110 PMID: 23763391

12. Farmer GW, Jabson JM, Bucholz KK, Bowen DJ. A population-based study of cardiovascular disease risk in sexual-minority women. Am J Public Health. 2013; 103(10):1845–1850. https://doi.org/10.2105/AJPH.2013.301258 PMID: 23948018

13. Dilley JA, Simmons KW, Boysun MJ, Pizacani BA, Stark MJ. Demonstrating the importance and feasibility of including sexual orientation in public health surveys: health disparities in the Pacific Northwest. Am J Public Health. 2010; 100(3):460–467. https://doi.org/10.2105/AJPH.2007.130336 PMID: 19696397

14. Conron KJ, Mimiaga MJ, Landers SJ. A population-based study of sexual orientation identity and gender differences in adult health. Am J Public Health. 2010; 100(10):1953–1960. https://doi.org/10.2105/AJPH.2009.174169 PMID: 20516373
15. Drabble L, Midanik LT, Trocki K. Reports of alcohol consumption and alcohol-related problems among homosexual, bisexual and heterosexual respondents: results from the 2000 National Alcohol Survey. J Stud Alcohol. 2005; 66(1):111–120. PMID: 15830911.

16. Agenor M, Peitzmeier S, Gordon AR, Haneuse S, Potter JE, Austin SB. Sexual orientation identity disparities in awareness and initiation of the human papillomavirus vaccine among U.S. women and girls: a national survey. Ann Intern Med. 2015; 163(2):99–106. https://doi.org/10.7326/M14-2108 PMID: 25961737

17. Matthews DD, Lee JG. A profile of North Carolina lesbian, gay, and bisexual health disparities, 2011. Am J Public Health. 2014; 104(6):e98–e105. https://doi.org/10.2105/AJPH.2013.301751 PMID: 124825240

18. Blosnich JR, Farmer GW, Lee JG, Silenzio VM, Bowen DJ. Health inequalities among sexual minority adults: evidence from ten U.S. states, 2010. Am J Prev Med. 2014; 46(4):337–349. https://doi.org/10.1016/j.amepre.2013.11.010 PMID: 24650836

19. Lick DJ, Durso LE, Johnson KL. Minority stress and physical health among sexual minorities. Perspect Psychol Sci. 2013; 8(5):521–548. https://doi.org/10.1177/1745691613497965 PMID: 26173210

20. Lewis NM. Mental health in sexual minorities: recent indicators, trends, and their relationships to place in North America and Europe. Health Place. 2009; 15(4):1029–1045. https://doi.org/10.1016/j.healthplace.2009.05.003 PMID: 19515600

21. Mayer KH, Bradford JB, Makadon HJ, Stall R, Goldhammer H, Landers S. Sexual and gender minority health: what we know and what needs to be done. Am J Public Health. 2008; 98(6):989–995. https://doi.org/10.2105/AJPH.2007.127811 PMID: 18445789

22. Daniel H, Butkus R, Health and Public Policy Committee of American College of Physicians. Lesbian, gay, bisexual, and transgender health disparities: executive summary of a policy position paper from the American College of Physicians. Ann Intern Med. 2015; 163(2):135–157. https://doi.org/10.7326/M14-2482 PMID: 25961598

23. Waterman L, Voss J. HPV, cervical cancer risks, and barriers to care for lesbian women. Nurse Pract. 2015; 40(1):46–53. https://doi.org/10.1097/01.NPR.0000457431.20036.5c PMID: 25437384

24. Apaydin KZ, Fontenot HB, Shtasel D, Dale SK, Borba CPC, Lathan CS, et al. Facilitators of and barriers to HPV vaccination among sexual and gender minority patients at a Boston community health center. Vaccine. 2018; 36(26):3868–3875. https://doi.org/10.1016/j.vaccine.2018.02.043 PMID: 29778516

25. Polek C, Hardie T. Changing HPV vaccination rates in bisexual and lesbian women. J Am Assoc Nurse Pract. 2017; 29(6):333–339. https://doi.org/10.1002/2327-6924.12453 PMID: 28332774

26. Thomas EA, Goldstone SE. Should I or shouldn’t I: decision making, knowledge and behavioral effects of quadrivalent HPV vaccination in men who have sex with men. Vaccine. 2011; 29(3):570–576. https://doi.org/10.1016/j.vaccine.2010.09.101 PMID: 20950728

27. Oliver SE, Hoots BE, Paz-Bailey G, Markowitz LE, Mettes E; NHBS Study Group. Increasing human papillomavirus vaccine coverage among men who have sex with men—National HIV Behavioral Surveillance, United States, 2014. J Acquir Immune Defic Syndr. 2017; 75 Suppl 3:S370–S374. https://doi.org/10.1016/j.ajิดs.2017.12.003 PMID: 28604441

28. Weinbaum CM, Lyerla R, Mackellar DA, Valleroy LA, Secura GM, Behel SK, et al. The young men’s survey phase II: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health. 2008; 98(8):839–845. https://doi.org/10.1015/AJPH.2006.109151 PMID: 18382012

29. Reiter PL, Brewer NT. Hepatitis B vaccination among a national sample of gay and bisexual men. Sex Transm Dis. 2011; 38(3):235–238. https://doi.org/10.1097/OLQ.0b013e3181f422bb PMID: 20842072

30. Mays VM, Yancey AK, Cochran SD, Weber M, Fielding JE. Heterogeneity of health disparities among African American, Hispanic, and Asian American women: unrecognized influences of sexual orientation. Am J Public Health. 2002 Apr; 92(4):632–9. PMID: 11919064.

31. Floyd SR, Pierce DM, Geraci SA. Preventive and primary care for lesbian, gay and bisexual patients. Am J Med Sci. 2016; 352(6):637–643. https://doi.org/10.1016/j.amjms.2016.05.008 PMID: 27916220

32. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012; 13(5):487–500. https://doi.org/10.1016/S1470-2045(12)70080-3 PMID: 22445259

33. Kates J, Ranji U, Beamesderfer A, Salganicoff A, Dawson L. Health and access to care and coverage for lesbian, gay, bisexual, and transgender individuals in the U.S. Available from: http://kff.org/disparities-policy/issue-brief/health-and-access-to-care-and-coverage-for-lesbian-gay-bisexual-and-transgender-individuals-in-the-u-s/

34. National Academy of Medicine. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Washington (DC): National Academies Press; 2011.
35. Buchmuller T, Carpenter CS. Disparities in health insurance coverage, access, and outcomes for individuals in same-sex versus different-sex relationships, 2000–2007. Am J Public Health. 2010; 100(3):489–95. https://doi.org/10.2105/AJPH.2009.160804 PMID: 20075319
36. Heck JE, Sell RL, Gorin SS. Health care access among individuals involved in same-sex relationships. Am J Public Health. 2006; 96(6):1111–8. https://doi.org/10.2105/AJPH.2005.062661 PMID: 16670230
37. Skopec L, Long SK. Lesbian, gay, and bisexual adults making gains in health insurance and access to care. Health Aff (Millwood). 2015; 34(10):1769–73. https://doi.org/10.1377/hlthaff.2015.0826 PMID: 26438755
38. Parsons VL, Moriarity C, Jonas K, Moore TF, Davis KE, Tompkins L. Design and estimation for the national health interview survey, 2006–2015. Vital Health Stat 2. 2014;(165):1–53. PMID: 24775908.
39. National Center for Health Statistics. 2015 National Health Interview Survey (NHIS) public use data release survey description. 2016. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/srvydesc.pdf
40. National Center for Health Statistics. 2014 National Health Interview Survey (NHIS) public use data release survey description. 2015. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2014/srvydesc.pdf
41. National Center for Health Statistics. 2013 National Health Interview Survey (NHIS) public use data release survey description. 2014. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2013/srvydesc.pdf
42. Centers for Disease Control and Prevention. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010; 59(12):363–368. PMID: 20360670.
43. Lu PJ, Ding H, Black CL. H1N1 and seasonal influenza vaccination of U.S. healthcare personnel, 2010. Am J Prev Med. 2012; 43(3):282–292. https://doi.org/10.1016/j.amepre.2012.05.005 PMID: 22898121
44. Lu PJ, Santibanez TA, Williams WW, Zhang J, Ding H, Bryan L, et al. Surveillance of influenza vaccination coverage—United States, 2007–08 through 2011–12 influenza seasons. MMWR Surveill Summ. 2013; 62(4):1–28. PMID: 24157710.
45. U.S. Department of Health and Human Services. Physical activity guidelines for Americans. 2008. Available from: https://health.gov/paguidelines/guidelines/adults.aspx
46. Gilbert LK, Levandowski BA, Scanlon KE, Peterson RS. A comparison of hepatitis A and hepatitis B measures among vaccinated and susceptible online men who have sex with men. Int J STD AIDS. 2010; 21(6):400–405. https://doi.org/10.1258/ijsa.2009.009010 PMID: 20606219
47. Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. Hepatitis B virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County, USA. AIDS Behav. 2014; 18 Suppl 3:248–255. https://doi.org/10.1007/s10461-013-0670-2 PMID: 24276792
48. Siconolfi DE, Halkitis PN, Rogers ME. Hepatitis vaccination and infection among gay, bisexual, and other men who have sex with men who attend gyms in New York City. Am J Mens Health. 2009; 3(2):141–149. https://doi.org/10.1177/1557988308315151 PMID: 19477727
49. Linkins RW, Chonwattana W, Holtz TH, Wasinrapree P, Chaikummao S, Varangrat A, et al. Hepatitis A and hepatitis B infection prevalence and associated risk factors in men who have sex with men, Bangkok, 2006–2008. J Med Virol. 2013; 85(9):1499–1505. https://doi.org/10.1002/jmv.23637 PMID: 23797893
50. Ndiaye SM, Hopkins DP, Shefer AM, Hinman AR, Briss PA, Rodewald L, et al. Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review. Am J Prev Med. 2005; 28(S Suppl):248–279. https://doi.org/10.1016/j.amepre.2005.02.016 PMID: 15894160
51. Gay and Lesbian Medical Association. Guidelines for care of lesbian, gay, bisexual, and transgender patients. Available from: http://www.glma.org/_data/n_0001/resources/live/GLMA%20guidelines%202006%20FINAL.pdf
52. Shiperd JC, Darling JE, Klap RS et al. Experiences in the veterans health administration and impact on healthcare utilization: comparisons between LGBT and non-LGBT women veterans. LGBT Health. 2018; 5(5):303–311. https://doi.org/10.1089/lgbt.2017.0179 PMID: 29979640
53. Whitehead J, Shaver J, Stephenson R. Outness, stigma, and primary health care utilization among rural LGBT populations. PLoS One. 2016;e0146139. https://doi.org/10.1371/journal.pone.0146139 PMID: 26731405
54. Ward BW, Dahhamer JM, Galinsky AM, Joestl SS. Sexual orientation and health among U.S. adults: National Health Interview Survey, 2013. Natl Health Stat Report. 2014;(77):1–10. PMID: 25025690.
55. Copen CE, Chandra A, Febo-Vazquez I. Sexual behavior, sexual attraction, and sexual orientation among adults aged 18–44 in the United States: Data from the 2011–2013 National Survey of Family Growth. Natl Health Stat Report. 2016;(88):1–14. PMID: 26766410.

56. Gallup. In US, more adults identifying as LGBT. 2017. Available from: http://www.gallup.com/poll/201731/lgbt-identification-rises.aspx

57. Williams Institute, UCLA School of Law. How many people are lesbian, gay, bisexual, and transgender? 2011. Available from: https://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf

58. Gonzales G, Blewett LA. National and state-specific health insurance disparities for adults in same-sex relationships. Am J Public Health. 2014; 104(2):e95–e104. https://doi.org/10.2105/AJPH.2013.301577 PMID: 24328616

59. Rath JM, Villanti AC, Rubenstein RA, Vallone DM. Tobacco use by sexual identity among young adults in the United States. Nicotine Tob Res. 2013; 15(11):1822–1831. https://doi.org/10.1093/ntrltt062 PMID: 23680918

60. Cochran SD, Bandiera FC, Mays VM. Sexual orientation-related differences in tobacco use and secondhand smoke exposure among US adults aged 20 to 59 years: 2003–2010 National Health and Nutrition Examination Surveys. Am J Public Health. 2013; 103(10):1837–1844. https://doi.org/10.2105/AJPH.2013.301423 PMID: 23948019

61. Zimmerman RK, Raymund M, Janosky JE, Nowalk MP, Fine MJ. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine. 2003; 21(13–14):1486–1491. PMID: 12615445.

62. Mac Donald R, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med. 1999; 16(3):173–177. PMID: 10198654.

63. Mangtani P, Shah A, Roberts JA. Validation of influenza and pneumococcal vaccine status in adults based on self-report. Epidemiol Infect. 2007; 135(1):139–143. https://doi.org/10.1017/S0950268806006479 PMID: 16740194

64. Willis BC, Ndiaye SM, Hopkins DP, Shefer A; Task Force on Community Preventive Services. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep. 2005; 54(RR-5):1–11. PMID: 15800472.

65. Rolnick SJ, Parker ED, Nordin JD, Hedblom BD, Wei F, Kerby T, et al. Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors? Vaccine. 2013; 31(37):3928–3935. https://doi.org/10.1016/j.vaccine.2013.06.041 PMID: 23806243